Nuclear factor-κB dysregulation in splenic marginal zone lymphoma: new therapeutic opportunities.

about

Nuclear factor-κB dysregulation in splenic marginal zone lymphoma: new therapeutic opportunities.

Item

http://www.wikidata.org/entity/Q43138254

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Nuclear factor-κB dysregulatio ...... new therapeutic opportunities.

@en

Nuclear factor-κB dysregulatio ...... new therapeutic opportunities.

@nl

type

Item

label

Nuclear factor-κB dysregulatio ...... new therapeutic opportunities.

@en

Nuclear factor-κB dysregulatio ...... new therapeutic opportunities.

@nl

prefLabel

Nuclear factor-κB dysregulatio ...... new therapeutic opportunities.

@en

Nuclear factor-κB dysregulatio ...... new therapeutic opportunities.

@nl

P1476

Nuclear factor-κB dysregulatio ...... new therapeutic opportunities.

@en

P2093

Davide Rossi

http://www.w3.org/2001/XMLSchema#string

P2860

BRAF mutations in hairy-cell leukemia

Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma

Splenic marginal-zone lymphoma: a distinct clinical and pathological entity.

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.

Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma.

Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes.

Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG).

Non-canonical NF-κB activation and abnormal B cell accumulation in mice expressing ubiquitin protein ligase-inactive c-IAP2.

Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.

P304

638-640

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.3324/HAEMATOL.2011.058362

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Luca Arcaini

P577

2012-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224897601

http://www.w3.org/2001/XMLSchema#string

P698

22556352

http://www.w3.org/2001/XMLSchema#string

P932

3342963

http://www.w3.org/2001/XMLSchema#string